What is the P/S ratio for Citius Oncology, Inc. (CTOR)?

The P/S ratio for CTOR stock is 11.58.

Citius Oncology, Inc.(CTOR)

Medical - Pharmaceuticals · Cranford, NY

$0.88+0.01 (+1.28%)

Delayed quote: Oct 6, 2026, 11:46 AM EDT

Compare

PS Ratio: 11.58

Name: Citius Oncology, Inc. (CTOR) PS Ratio — historical time series
Creator: TGMCharts

Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

Is the P/S ratio high or low?

The P/S ratio of 11.58 is 30% below its estimated 1-year average of 16.63, near the low end of its estimated 1-year range (8.14–27.05).

As of 2026-10-06T15:51:07.497Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:51:07.497Z.

Quote observation: 2026-10-06T15:46:22.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 82,260,471
TTM revenue · period ending 2026-06-30: 7,105,197

FMP input reference: e47236677832b0178bb4e4de0ecbdefb2e069a6eb9feaf5a3a870b06349bdf9c

P/E Ratio|Gross Margin|Revenue Growth|All Metrics

PS Ratio

CTOR PS Ratio Chart

11.58

Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2026-10-05.

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CTOR PS Ratio Metrics

PS RATIO

11.58

PS RATIO AVG TTM

N/A

PS RATIO AVG 3Y

N/A

PS RATIO AVG 5Y

N/A

PS RATIO AVG 10Y

N/A

PS RATIO AVG 15Y

N/A

PS RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

4.17

median of 475 covered companies

CURRENT VS SECTOR MEDIAN

+177.70%

vs the sector median at left

CTOR Competitors' PS Ratio

CTOR

Citius Oncology, Inc.

Current

Market Cap

$82.26M

PS Ratio

11.58

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LNSR

LENSAR Inc

vs CTOR

Market Cap

$82.29M

PS Ratio

1.37

TTM Avg

2.06

3Y Avg

1.84

5Y Avg

1.67

NTRB

Nutriband Inc.

vs CTOR

Market Cap

$80.47M

PS Ratio

49.75

TTM Avg

25.94

3Y Avg

25.30

5Y Avg

23.23

MNOV

MediciNova, Inc.

vs CTOR

Market Cap

$82.75M

PS Ratio

89.89

TTM Avg

216.46

3Y Avg

165.81

5Y Avg

579.35

ACRV

Acrivon Therapeutics, Inc. Common Stock

vs CTOR

Market Cap

$83.04M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LUNG

Pulmonx Corporation

vs CTOR

Market Cap

$79.98M

PS Ratio

0.91

TTM Avg

0.79

3Y Avg

2.77

5Y Avg

7.10

PMN

ProMIS Neurosciences, Inc.

vs CTOR

Market Cap

$85.55M

PS Ratio

N/A

TTM Avg

11653.16

3Y Avg

16737.74

5Y Avg

42439.00

CGTX

Cognition Therapeutics, Inc.

vs CTOR

Market Cap

$85.01M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INO

Inovio Pharmaceuticals, Inc.

vs CTOR

Market Cap

$78.76M

PS Ratio

N/A

TTM Avg

596.04

3Y Avg

341.95

5Y Avg

283.35

CRDF

Cardiff Oncology, Inc.

vs CTOR

Market Cap

$85.17M

PS Ratio

167.65

TTM Avg

221.52

3Y Avg

228.25

5Y Avg

248.51

NAME	MARKET CAP	PS RATIO	TTM	3Y	5Y
Citius Oncology, Inc. (CTOR)	$82.26M	11.58	N/A	N/A	N/A
LENSAR Inc (LNSR)vs ›	$82.29M	1.37	2.06	1.84	1.67
Nutriband Inc. (NTRB)vs ›	$80.47M	49.75	25.94	25.30	23.23
MediciNova, Inc. (MNOV)vs ›	$82.75M	89.89	216.46	165.81	579.35
Acrivon Therapeutics, Inc. Common Stock (ACRV)vs ›	$83.04M	N/A	N/A	N/A	N/A
Pulmonx Corporation (LUNG)vs ›	$79.98M	0.91	0.79	2.77	7.10
ProMIS Neurosciences, Inc. (PMN)vs ›	$85.55M	N/A	11653.16	16737.74	42439.00
Cognition Therapeutics, Inc. (CGTX)vs ›	$85.01M	N/A	N/A	N/A	N/A
Inovio Pharmaceuticals, Inc. (INO)vs ›	$78.76M	N/A	596.04	341.95	283.35
Cardiff Oncology, Inc. (CRDF)vs ›	$85.17M	167.65	221.52	228.25	248.51

How this was calculated

Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.

Revenue calculation and filing references
Fiscal period	Revenue	Source
Q4 FY2025Period ended 2025-09-30	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30
Q1 FY2026Period ended 2025-12-31	$3,944,111	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-31
Q2 FY2026Period ended 2026-03-31	$1,667,298	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-15
Q3 FY2026Period ended 2026-06-30	$1,493,788	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-30
TTM revenue	$7,105,197

Current P/S: $82,260,471 market capitalization ÷ $7,105,197 TTM revenue = 11.58x.

Market capitalization source: FMP quote. Quote observed 2026-10-06T15:46:22.000Z. Latest revenue period ended 2026-06-30.

Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.

P/S vs. estimated history

At 11.58, P/S is below its estimated 1-year median — higher than 20% of readings in its estimated 1-year history.

estimated 1-year low

8.14

median

14.83

estimated 1-year high

27.05

estimated 1-year lowestimated 1-year high

Sales Valuation

P/S Ratio

11.58

Market Cap / Trailing Twelve-Month Revenue

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PS Ratio FAQ

What is the P/S ratio for Citius Oncology, Inc. (CTOR)?: The P/S ratio for CTOR stock is 11.58.
Is Citius Oncology, Inc.'s P/S ratio high or low?: The P/S ratio of 11.58 is 30% below its estimated 1-year average of 16.63, near the low end of its estimated 1-year range (8.14–27.05).

CTOR PS Ratio History

DATE	PS RATIO
2026-10-05	13.26
2026-10-02	14.43
2026-10-01	14.88
2026-09-30	15.34
2026-09-29	15.94
2026-09-28	15.64
2026-09-25	15.94
2026-09-24	15.94
2026-09-23	15.34
2026-09-22	16.25
2026-09-21	15.94
2026-09-18	17.31
2026-09-17	15.49
2026-09-16	14.48
2026-09-15	13.00
2026-09-14	14.27
2026-09-11	13.93
2026-09-10	13.82
2026-09-09	14.27
2026-09-08	14.11
2026-09-04	13.06
2026-09-03	12.03
2026-09-02	11.81
2026-09-01	11.39
2026-08-31	11.59
2026-08-28	11.78
2026-08-27	12.00
2026-08-26	11.95
2026-08-25	12.30
2026-08-24	11.39
2026-08-21	11.29
2026-08-20	11.53
2026-08-19	11.43
2026-08-18	10.67
2026-08-17	11.24
2026-08-14	13.82
2026-08-13	12.55
2026-08-12	12.32
2026-08-11	11.08
2026-08-10	11.20
2026-08-07	11.43
2026-08-06	11.54
2026-08-05	11.92
2026-08-04	10.02
2026-08-03	9.50
2026-07-31	8.99
2026-07-30	8.71
2026-07-29	8.14
2026-07-28	8.22
2026-07-27	8.44
2026-07-24	8.54
2026-07-23	8.78
2026-07-22	8.70
2026-07-21	8.66
2026-07-20	8.66
2026-07-17	10.46
2026-07-16	10.36
2026-07-15	10.46
2026-07-14	9.87
2026-07-13	10.70
2026-07-10	10.49
2026-07-09	10.95
2026-07-08	11.08
2026-07-07	10.78
2026-07-06	10.76
2026-07-02	10.33
2026-07-01	10.69
2026-06-30	11.59
2026-06-29	12.32
2026-06-26	11.05
2026-06-25	11.76
2026-06-24	12.22
2026-06-23	12.21
2026-06-22	12.62
2026-06-18	11.94
2026-06-17	11.77
2026-06-16	11.77
2026-06-15	12.13
2026-06-12	11.84
2026-06-11	12.34
2026-06-10	12.24
2026-06-09	12.83
2026-06-08	14.26
2026-06-05	13.90
2026-06-04	14.19
2026-06-03	13.90
2026-06-02	13.95
2026-06-01	14.12
2026-05-29	14.22
2026-05-28	14.38
2026-05-27	15.85
2026-05-26	15.33
2026-05-22	14.97
2026-05-21	14.78
2026-05-20	14.72
2026-05-19	14.76
2026-05-18	14.78
2026-05-15	21.36
2026-05-14	21.83
2026-05-13	21.89
2026-05-12	20.03
2026-05-11	20.05
2026-05-08	20.11
2026-05-07	19.98
2026-05-06	20.16
2026-05-05	21.22
2026-05-04	20.40
2026-05-01	20.95
2026-04-30	19.51
2026-04-29	19.07
2026-04-28	19.22
2026-04-27	19.37
2026-04-24	19.45
2026-04-23	21.68
2026-04-22	20.84
2026-04-21	19.96
2026-04-20	20.49
2026-04-17	19.47
2026-04-16	17.86
2026-04-15	18.41
2026-04-14	17.30
2026-04-13	15.07
2026-04-10	14.97
2026-04-09	14.64
2026-04-08	14.24
2026-04-07	14.72
2026-04-06	15.24
2026-04-02	15.59
2026-04-01	14.37
2026-03-31	13.75
2026-03-30	10.93
2026-03-27	11.35
2026-03-26	12.00
2026-03-25	12.82
2026-03-24	12.92
2026-03-23	13.87
2026-03-20	14.26
2026-03-19	15.32
2026-03-18	15.12
2026-03-17	16.98
2026-03-16	17.87
2026-03-13	18.02
2026-03-12	20.18
2026-03-11	20.69
2026-03-10	22.18
2026-03-09	22.40
2026-03-06	22.62
2026-03-05	23.73
2026-03-04	24.17
2026-03-03	23.51
2026-03-02	23.95
2026-02-27	24.84
2026-02-26	24.17
2026-02-25	24.61
2026-02-24	24.61
2026-02-23	25.28
2026-02-20	25.72
2026-02-19	26.83
2026-02-18	25.95
2026-02-17	26.17
2026-02-13	27.05
2026-02-12	26.17
2026-02-11	25.06
2026-02-10	25.06
2026-02-09	24.61
2026-02-06	25.06
2026-02-05	24.61
2026-02-04	25.50
2026-02-03	24.61
2026-02-02	23.95
2026-01-30	23.51
2026-01-29	24.39
2026-01-28	24.17
2026-01-27	24.39
2026-01-26	24.39
2026-01-23	25.06
2026-01-22	24.84
2026-01-21	25.50
2026-01-20	23.28
2026-01-16	23.28
2026-01-15	23.95
2026-01-14	24.39
2026-01-13	24.17
2026-01-12	23.73
2026-01-09	24.17
2026-01-08	25.06
2026-01-07	25.50
2026-01-06	26.61
2026-01-05	25.50
2026-01-02	23.95

PS Ratio: 11.58

CTOR PS Ratio Chart

CTOR PS Ratio Metrics

CTOR Competitors' PS Ratio

P/S vs. estimated history

Sales Valuation

PS Ratio Formula & Definition

PS Ratio FAQ

CTOR PS Ratio History

Related Metrics